Founded: 2014
Manchester Project Inc Is a registered Non-Profit Organization 501(c)3. We are dedicated to spreading ALS(Lou Gehrig’s Disease) awareness, raising funds for viable and leading-edge treatments for ALS through our Outreach and Gifting programs. We continue to educate our ALS Family which will allow our pALS (people with living with ALS) to live happier and more productive lives UNTIL A CURE IS FOUND.
On July 7, 2011, I (Mark Manchester) was diagnosed with ALS. After undergoing evaluations by several doctors, the diagnosis was confirmed. I was really in denial at that point but after a couple of months, I realized I could not just curl up and die. I knew I had to do something so I adopted the win-win approach for this disease. I enrolled in Trials that could possibly help my generation or future generations of pALS, that would be a “win”. If this was the Lords way of taking me home then that would also be a “win”. We founded “Manchester Project INC” in 2014 to continue to help people Living with ALS (pALS) and their care givers (cALS).
Please Help and Donate to “Manchester Project Inc”
No amount is too small
What is ALS(Lou Gehrig’s Disease)?
ALS was first found in 1869 by French neurologist Jean-Martin Charcot, but it wasn’t until 1939 that Lou Gehrig brought national and international attention to the disease. Ending the career of one of the most beloved baseball players of all time, the disease is still most closely associated with his name. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed.